• Baskar Viswanathan DEPARTMENT OF CHEMISTRY, THE NEW COLLEGE, New No. 147, Old No. 87, Peter’s Road, Chennai, Tamil Nadu 600014
  • Shabeer Tks DEPARTMENT OF CHEMISTRY, THE NEW COLLEGE, New No. 147, Old No. 87, Peter’s Road, Chennai, Tamil Nadu 600014



Objective: A pharmacokinetic study is a cumbersome process in clinical research. It is very important in target validation and in shifting a lead
compound into a drug. Our major objective was to reveal the most important physiochemical characters of the plant-based anti-oxidants in align with
human physiology. The in silico studies can preferably be the best solution to identify the physiologically-based pharmacokinetic (PBPK) behavior of
the anti-oxidants.
Methods: Anti-oxidants are found in many foods including fruits and vegetables. Few of the important anti-oxidants, i.e. around 10 plant-based antioxidant
compounds were taken for this research. These compounds were evaluated based on their pharmacokinetic parameters. The properties such
as Lipinski's rule of 5, absorption, distribution, metabolism, excretion, and toxicity (ADMET) of the compounds were screened thoroughly with the
help of tools such as molinspiration and gastroplus.
Results: The physiological studies of these compounds had shown different compartmental absorptions of the compound in the human gastrointestinal
tract. Certain compounds were found to pass the physiological barriers and had the ability to become a drug. The compounds were filtered using the
risk and toxicity factors. These risk factors caused the compounds to fail in the process of becoming a drug.
Conclusion: The compounds which passed the PBPK studies were eligible to become a drug. Of the 10 compounds investigated, eugenol, gingerol,
zingerone, and geraniol were found to have higher fraction of absorption to become a drug. Out of these compounds, the compounds gingerol and
eugenol have shown the best factor of absorption, and hence, have a better probability of becoming a drug.
Keywords: Anti-oxidants, Lipinski, Absorption, Distribution, Metabolism, Excretion and toxicity, Physiological properties, GastroPlus, In silico.

Author Biographies

Baskar Viswanathan, DEPARTMENT OF CHEMISTRY, THE NEW COLLEGE, New No. 147, Old No. 87, Peter’s Road, Chennai, Tamil Nadu 600014

Research expertise are in the area of nano drug delivery systems, pharmacokinetics and other social value creating project such as diabetes management. 

I'm part of various research group both in institution and industry and served as principal investigator. 

Shabeer Tks, DEPARTMENT OF CHEMISTRY, THE NEW COLLEGE, New No. 147, Old No. 87, Peter’s Road, Chennai, Tamil Nadu 600014

My thrust area of research is polymer chemistry and produced novel polymers which has several application in clinical health sector.


Parnes RB. Antioxidants: What you need to know. How Stuff Works. Available from: [Last accessed on 2002 Nov 26].

Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003;33(5):469-503.

Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009;9(4):419-26.

Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70(3):461-77.

Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011;89(2):259-67.

Haddad S, Béliveau M, Tardif R, Krishnan K. A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures 2001;63(1):125-31.

Timchalk C, Nolan RJ, Mendrala AL, Dittenber DA, Brzak KA, Mattsson JL. A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol Sci 2002;66(1):34-53.

Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 2009;24(1):16-24.

Suenderhauf C, Parrott N. A physiologically based pharmacokinetic model of the minipig: Data compilation and model implementation. Pharm Res 2013;30(1):1-15.

Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Deliv Rev 1996;19:359-76.

Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50 Suppl 1:S41-67.

PubChem: Available from:

Molinspiration: Available from:

GastroPlus: Available from:

Taft CA, Da Silva VB, Da Silva CH. Current topics in computer-aided drug design. J Pharm Sci 2008;97(3):1089-98.

Lipinski CA. Lead - and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 2004;1(4):337-41.

van de Waterbeemd H, Gifford E. ADMET in silico modelling: Towards prediction paradise? Nat Rev Drug Discov 2003;2(3):192-204.

Butina D, Segall MD, Frankcombe K. Predicting ADME properties in silico: Methods and models. Drug Discov Today 2002;7(11):S83-8.

Gleeson MP, Hersey A, Hannongbua S. In-silico ADME models: A general assessment of their utility in drug discovery applications. Curr Top Med Chem 2011;11(4):358-81.

Baskar V, Jayalakshmi C, Pavithra N, Grite VS. Validating therapeutically active phytochemical compounds for anti-ageing by in silico pharmacokinetic approach. J Biol Inf Sci 2014;3(1):1-7.

Punt A, Schiffelers MJ, Jean Horbach G, van de Sandt JJ, Groothuis GM, Rietjens IM, et al. Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice. Regul Toxicol Pharmacol 2011;61(1):105-14.

Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 2012;39(6):711-23.

Yang RS, el-Masri HA, Thomas RS, Constan AA, Tessari JD. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. Toxicol Lett 1995;79(1-3):193-200.

Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. Eur J Pharm Sci 2012;47(2):375-86.

Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999;1(1):55-68.

Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010;75(1):1-18.

Ray A, Gulati K. Current Trends in Pharmacology: Bioavailability and Bioequivalence Studies. India: IK International Private Ltd.; 2007.

Malothu N, Veldandi UK, Yellu NR, Yadala N, Devarakonda RK. Population pharmacokinetics of 5-flouro uracil in Indian cancer patient population. Asian J Pharm Clin Res 2010;3(3);197-200.

Rice-Evans CA, Miller NJ. Antioxidant activities of flavonoids as bioactive components of food. Biochem Soc Trans 1996;24(3):790-5.



How to Cite

Viswanathan, B., S. Tks, A. R. Chida, and D. M. Stanly. “PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR PLANT-BASED ANTI-OXIDANT DRUGS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 9, Dec. 2016, pp. 223-9, doi:10.22159/ajpcr.2016.v9s3.7894.



Original Article(s)